CD276 and Patent ductus arteriosus: Moreover, targeting B7-H3 with the B7-H3.CAR (chimeric antigen receptor)-T cells derived from the monoclonal antibody effectively controlled tumor growth for up to 70 days post treatment in PDA xenograft models (57).